Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001144204-11-044597
Filing Date
2011-08-08
Accepted
2011-08-08 17:01:41
Documents
11
Period of Report
2011-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT v229284_10q.htm 10-Q 810029
2 EXHIBIT 31.1 v229284_ex31-1.htm EX-31.1 17416
3 EXHIBIT 31.2 v229284_ex31-2.htm EX-31.2 17008
4 EXHIBIT 32.1 v229284_ex32-1.htm EX-32.1 6585
5 EXHIBIT 32.2 v229284_ex32-2.htm EX-32.2 6777
  Complete submission text file 0001144204-11-044597.txt   2602496

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT kerx-20110630.xml EX-101.INS 332226
7 XBRL TAXONOMY EXTENSION SCHEMA kerx-20110630.xsd EX-101.SCH 10911
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE kerx-20110630_cal.xml EX-101.CAL 31860
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE kerx-20110630_def.xml EX-101.DEF 76909
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE kerx-20110630_lab.xml EX-101.LAB 88224
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kerx-20110630_pre.xml EX-101.PRE 83430
Mailing Address
Business Address 750 LEXINGTON AVENUE . NEW YORK NY 10022 212-531-5965
KERYX BIOPHARMACEUTICALS INC (Filer) CIK: 0001114220 (see all company filings)

EIN.: 134087132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-30929 | Film No.: 111017901
SIC: 2834 Pharmaceutical Preparations